Literature DB >> 17027822

Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men.

Gilles Chironi1, Christine Dosquet, Muriel Del-Pino, Nicolas Denarie, Jean-Louis Megnien, Ludovic Drouet, Claire Bal dit Sollier, Jaime Levenson, Alain Simon.   

Abstract

BACKGROUND: Relations of mediators of inflammation and hemostasis with preclinical atherosclerosis have been poorly analyzed. The aim of this study was to test potential associations of these blood markers with indicators of cardiovascular risk and atherosclerotic burden in asymptomatic, nonsmoking, hypercholesterolemic men.
METHODS: A total of 87 men underwent cardiovascular risk assessment by means of 10-year Framingham risk calculation (median 9%) and atherosclerotic burden evaluation by means of ultrasonographic measurement of common carotid intima-media thickness and assessment of atherosclerotic plaques at three arterial sites (three-site plaques).
RESULTS: Of the markers C-reactive protein, tumor necrosis factor-alpha, interleukin-10, factor VIIc, fibrinogen, plasminogen activator inhibitor-activator, soluble intercellular adhesion molecule-1, soluble P-selectin (sP-selectin), and von Willebrand factor, only sP-selectin was positively and independently associated with high Framingham risk score (>9%) (71.7 +/- 3.6 ng/mL, n = 33 v 59.6 +/- 2.8, n = 54; mean +/- SEM; P < .05) and with three-site plaques (75.4 +/- 5.7 ng/mL, n = 14 v 62.0 +/- 2.5, n = 73; P < .05). After adjustment for all of the above markers and for cardiovascular risk factors, odd ratios of having high Framingham risk and three-site plaques were 3.38 (1.43 to 10.21) and 5.23 (1.74 to 23.52) respectively, per 1-standard deviation increase in sP-selectin.
CONCLUSIONS: These results confirm that among several hemostasis and inflammation mediators, only sP-selectin blood level was associated with preclinical atherosclerosis. It might confer to sP-selectin measurement a clinical usefulness for detecting and managing high cardiovascular risk in primary prevention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17027822     DOI: 10.1016/j.amjhyper.2006.03.016

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

1.  Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis.

Authors:  G Chironi; C Pagnoux; A Simon; M Pasquinelli-Balice; M Del-Pino; J Gariepy; L Guillevin
Journal:  Heart       Date:  2006-08-29       Impact factor: 5.994

2.  Quantitative trait locus analysis of circulating adhesion molecules in hyperlipidemic apolipoprotein E-deficient mice.

Authors:  Zuobiao Yuan; Zhiguang Su; Toru Miyoshi; Jessica S Rowlan; Weibin Shi
Journal:  Mol Genet Genomics       Date:  2008-08-13       Impact factor: 3.291

3.  Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-African young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Authors:  Alexander P Reiner; Christopher S Carlson; Bharat Thyagarajan; Mark J Rieder; Joseph F Polak; David S Siscovick; Deborah A Nickerson; David R Jacobs; Myron D Gross
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-05       Impact factor: 8.311

4.  Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis.

Authors:  Janka Kisucka; Anil K Chauhan; Bing-Qiao Zhao; Ian S Patten; Ayce Yesilaltay; Monty Krieger; Denisa D Wagner
Journal:  Blood       Date:  2009-04-06       Impact factor: 22.113

5.  Milan PM1 induces adverse effects on mice lungs and cardiovascular system.

Authors:  Francesca Farina; Giulio Sancini; Eleonora Longhin; Paride Mantecca; Marina Camatini; Paola Palestini
Journal:  Biomed Res Int       Date:  2012-12-27       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.